Bio-Techne Corp (TECH) Stock Price & How to Invest

Bio-Techne Corporation is a global life-sciences tools and diagnostics company based in Minnesota. It supplies the reagents, proteins, antibodies, immunoassays, and analytical instruments that biopharma and academic researchers use in drug discovery, cell and gene therapy, and diagnostics. The portfolio spans three customer-facing brands (R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics) and is reported in two segments: Protein Sciences, the larger piece at roughly three-quarters of revenue, and Diagnostics and Spatial Biology, roughly the remaining quarter. Because it sells the consumables and instruments that sit upstream of research and manufacturing, Bio-Techne's results track biopharma and academic funding cycles rather than any single end product, with growth pockets in GMP proteins for cell therapy and its COMET spatial-biology platform.

The defining event of 2026 is a takeover. On June 25, 2026, Merck KGaA (the German science and technology group, distinct from the US company Merck & Co.) agreed to acquire Bio-Techne for $73 per share in cash, an enterprise value of roughly $11.3 billion and about a 36% premium to the prior one-month average price. The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and a Bio-Techne shareholder vote. Since the announcement, the stock has traded near the cash offer, which changes the investment picture: an investor buying today is mostly betting on whether and when the merger completes, with limited upside above the deal price and downside if it falls through. Underlying operating results in fiscal 2026 were mixed, with soft organic growth in Protein Sciences offset by strength in GMP proteins and spatial biology.

The central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from regulatory objections, the shareholder vote, or a change in conditions) could send shares back toward pre-announcement levels, while the upside above the deal price is limited. Timing risk matters too, since the money is tied up until the transaction completes in late 2026 or early 2027. If the deal fell through, the stock would again trade on fundamentals, where organic growth in Protein Sciences has been soft and demand depends on biotech and academic funding cycles that remain under pressure. Foreign-exchange swings, integration uncertainty for the combined entity, and the general execution risk of a large cross-border merger add further variables outside an individual investor's control.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Bio-Techne Corp's investor relations page or your broker.

• Situation: Pending acquisition by Merck KGaA at $73 per share in cash (announced June 25, 2026); verify live figures and deal status before acting
• Enterprise value of deal: ~$11.3 billion, roughly a 36% premium to the prior one-month average price
• Recent share price: Trading near the low $70s, close to the cash offer, which caps upside and signals the market is pricing deal completion
• Market cap: ~$11 billion (approximate; moves with the deal spread)
• Segments: Protein Sciences (~75% of revenue) and Diagnostics and Spatial Biology (~25%); fiscal 2026 organic growth was soft in the core, stronger in GMP proteins and spatial biology
• Expected close: Late 2026 or early 2027, subject to regulatory approvals and a shareholder vote

Figures are approximate and tied to the asOf date; verify live numbers and the current status of the Merck KGaA transaction before acting. Because the stock trades near the $73 cash offer, traditional valuation multiples matter less than the merger: the return an investor earns from here is largely the spread between the market price and the deal price, adjusted for the odds and timing of closing. If the deal completes, holders receive $73 per share in cash; if it breaks, the stock would re-rate to standalone fundamentals.

There are three common ways to get TECH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TECH sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where TECH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Bio-Techne is a high-quality life-sciences tools and diagnostics business, but the story in mid-2026 is the pending $73-per-share cash takeover by Merck KGaA. The stock now behaves like a deal-completion play, so the key question is your view on the merger closing, not the operating outlook.